MedPath

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Phase 2
Completed
Conditions
Hilar Cholangiocarcinoma
Undifferentiated Gallbladder Carcinoma
Gallbladder Adenocarcinoma
Recurrent Extrahepatic Bile Duct Carcinoma
Recurrent Gallbladder Carcinoma
Unresectable Gallbladder Carcinoma
Extrahepatic Bile Duct Adenocarcinoma
Gallbladder Adenocarcinoma With Squamous Metaplasia
Unresectable Extrahepatic Bile Duct Carcinoma
Interventions
Registration Number
NCT01093222
Lead Sponsor
National Cancer Institute (NCI)
Brief Summary

This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma. Sorafenib tosylate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

Detailed Description

OBJECTIVES:

I. To assess the progression-free survival in patients with unresectable or metastatic gallbladder carcinoma or cholangiocarcinoma treated with the combination of sorafenib (sorafenib tosylate) and erlotinib (erlotinib hydrochloride).

II. To assess the overall survival in patients with unresectable or metastatic gallbladder carcinoma or cholangiocarcinoma treated with the combination of sorafenib and erlotinib.

III. To assess the objective response rate. IV. To assess the frequency and severity of toxicities. V. To collect specimens for banking for future research.

OUTLINE: This is a multicenter study.

Patients receive sorafenib tosylate orally (PO) twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up every 6 months for 3 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Cytologically or pathologically confirmed gallbladder carcinoma or cholangiocarcinoma

    • No ampullary carcinoma
  • Locally advanced unresectable or distant metastatic disease

  • Measurable disease

  • Patients with biliary obstruction must have decompression of the biliary tree by ERCP and stenting or percutaneous drainage

  • No prior systemic treatment for metastatic or unresectable locally advanced disease

  • No known brain metastases

  • Zubrod performance status of 0-1

  • Leukocyte count ≥ 3,000/mm^3

  • ANC ≥ 1,000/mm^3

  • Platelet count ≥100,000/mm^3

  • Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

    • For patient who had decompression of the biliary tree within the past 14 days, stability of the bilirubin level needs to be confirmed with two measurements within 5 to 7 days of each other
  • Serum albumin ≥ 2.5 g/dL

  • AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for liver metastases)

  • Creatinine clearance ≥ 60 mL/min

  • Not pregnant or nursing

  • Fertile patients must agree to use effective contraception

  • No active biliary sepsis

  • No bleeding diathesis

  • No uncontrolled or clinically significant cardiovascular disease, including any of the following:

    • Myocardial infarction within the past 6 months
    • Uncontrolled angina within the past 6 months
    • NYHA class II-IV congestive heart failure
    • Grade 3 cardiac valve dysfunction
    • Cardiac arrhythmia not controlled by medication
    • History of stroke or transient ischemic attack within the past 6 months
    • History of arterial thrombotic event of any type in the past 6 months
  • No uncontrolled hypertension, as evidenced by systolic BP ≥ 150 mm Hg or diastolic BP ≥ 100 mm Hg, within the past 28 days

  • Must be able to swallow and tolerate oral medications

    • No gastrointestinal tract disease or prior abdominal surgery that results in an inability to absorb oral medication
  • No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free within the past 3 years

  • No concurrent grapefruit or its juice

  • At least 6 months since 1 adjuvant or neoadjuvant regimen of chemotherapy, hormonal therapy, immunotherapy, radiotherapy (to < 25% of bone marrow only), or chemoradiotherapy before documented recurrence or metastatic disease

  • No prior treatment with any antiangiogenic agent or any EGFR inhibitors for any reason

  • Concurrent multiple anti-hypertensive medications allowed

  • No plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other therapy, including herbal or alternative medications for treatment of cancer

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Treatment (sorafenib tosylate and erlotinib hydrochloride)Sorafenib TosylatePatients receive sorafenib tosylate PO twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment (sorafenib tosylate and erlotinib hydrochloride)Erlotinib HydrochloridePatients receive sorafenib tosylate PO twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measures
NameTimeMethod
Progression-free SurvivalUp to 3 years

From date of registration to date of first documentation of progression or symptomatic deterioration (as defined in protocol), or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact.

Secondary Outcome Measures
NameTimeMethod
Overall SurvivalUp to 3 years

From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.

Objective ResponseUp to 3 years

Complete response (CR) is complete disappearance of all target and non-target lesions, no new lesions and no disease related symptoms. Partial response (PR) is a greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. Confirmed response is two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration. Partial response is two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration. Unconfirmed CR is one objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR is one objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR.

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study DrugUp to 3 years

Only adverse events that are possibly, probably or definitely related to study drug are reported.

Trial Locations

Locations (141)

Doctors Hospital

🇺🇸

Columbus, Ohio, United States

University of Washington Medical Center

🇺🇸

Seattle, Washington, United States

Sutter Cancer Research Consortium

🇺🇸

Novato, California, United States

Wenatchee Valley Hospital and Clinics

🇺🇸

Wenatchee, Washington, United States

UF Cancer Center at Orlando Health

🇺🇸

Orlando, Florida, United States

Oncare Hawaii Inc-POB II

🇺🇸

Honolulu, Hawaii, United States

Queen's Medical Center

🇺🇸

Honolulu, Hawaii, United States

Straub Clinic and Hospital

🇺🇸

Honolulu, Hawaii, United States

University of Hawaii Cancer Center

🇺🇸

Honolulu, Hawaii, United States

The Cancer Center of Hawaii-Liliha

🇺🇸

Honolulu, Hawaii, United States

Saint Joseph Health Center

🇺🇸

Kansas City, Missouri, United States

North Kansas City Hospital

🇺🇸

Kansas City, Missouri, United States

Research Medical Center

🇺🇸

Kansas City, Missouri, United States

Gaston Memorial Hospital

🇺🇸

Gastonia, North Carolina, United States

Riverside Methodist Hospital

🇺🇸

Columbus, Ohio, United States

Columbus CCOP

🇺🇸

Columbus, Ohio, United States

Kettering Medical Center

🇺🇸

Kettering, Ohio, United States

Knox Community Hospital

🇺🇸

Mount Vernon, Ohio, United States

Licking Memorial Hospital

🇺🇸

Newark, Ohio, United States

Evergreen Hematology and Oncology PS

🇺🇸

Spokane, Washington, United States

Rocky Mountain Oncology

🇺🇸

Casper, Wyoming, United States

Cancer Center of Kansas - Dodge City

🇺🇸

Dodge City, Kansas, United States

Welch Cancer Center

🇺🇸

Sheridan, Wyoming, United States

The University of Arizona Medical Center-University Campus

🇺🇸

Tucson, Arizona, United States

Loma Linda University Medical Center

🇺🇸

Loma Linda, California, United States

USC / Norris Comprehensive Cancer Center

🇺🇸

Los Angeles, California, United States

Fremont - Rideout Cancer Center

🇺🇸

Marysville, California, United States

UC Irvine Health/Chao Family Comprehensive Cancer Center

🇺🇸

Orange, California, United States

Poudre Valley Hospital

🇺🇸

Fort Collins, Colorado, United States

Valley Medical Oncology Consultants

🇺🇸

Pleasanton, California, United States

Saint Francis Hospital and Medical Center

🇺🇸

Hartford, Connecticut, United States

Northeast Georgia Medical Center

🇺🇸

Gainesville, Georgia, United States

Memorial University Medical Center

🇺🇸

Savannah, Georgia, United States

Pali Momi Medical Center

🇺🇸

Aiea, Hawaii, United States

Maui Memorial Medical Center

🇺🇸

Wailuku, Hawaii, United States

Decatur Memorial Hospital

🇺🇸

Decatur, Illinois, United States

Central Illinois CCOP

🇺🇸

Decatur, Illinois, United States

Loyola University Medical Center

🇺🇸

Maywood, Illinois, United States

Saint Francis Hospital and Health Centers

🇺🇸

Beech Grove, Indiana, United States

Memorial Medical Center

🇺🇸

Springfield, Illinois, United States

Cancer Center of Kansas - Chanute

🇺🇸

Chanute, Kansas, United States

Reid Hospital and Health Care Services

🇺🇸

Richmond, Indiana, United States

Cancer Center of Kansas - El Dorado

🇺🇸

El Dorado, Kansas, United States

Cancer Center of Kansas - Fort Scott

🇺🇸

Fort Scott, Kansas, United States

Cancer Center of Kansas-Independence

🇺🇸

Independence, Kansas, United States

Cancer Center of Kansas-Kingman

🇺🇸

Kingman, Kansas, United States

Lawrence Memorial Hospital

🇺🇸

Lawrence, Kansas, United States

Cancer Center of Kansas-Liberal

🇺🇸

Liberal, Kansas, United States

Cancer Center of Kansas - Newton

🇺🇸

Newton, Kansas, United States

Menorah Medical Center

🇺🇸

Overland Park, Kansas, United States

Saint Luke's South Hospital

🇺🇸

Overland Park, Kansas, United States

Cancer Center of Kansas - Parsons

🇺🇸

Parsons, Kansas, United States

Kansas City CCOP

🇺🇸

Prairie Village, Kansas, United States

Associates In Womens Health

🇺🇸

Wichita, Kansas, United States

Cancer Center of Kansas - Pratt

🇺🇸

Pratt, Kansas, United States

Shawnee Mission Medical Center

🇺🇸

Shawnee Mission, Kansas, United States

Cancer Center of Kansas - Wellington

🇺🇸

Wellington, Kansas, United States

Cancer Center of Kansas - Main Office

🇺🇸

Wichita, Kansas, United States

Via Christi Regional Medical Center

🇺🇸

Wichita, Kansas, United States

Boston Medical Center

🇺🇸

Boston, Massachusetts, United States

Cancer Center of Kansas - Winfield

🇺🇸

Winfield, Kansas, United States

Wichita CCOP

🇺🇸

Wichita, Kansas, United States

Oakwood Hospital and Medical Center

🇺🇸

Dearborn, Michigan, United States

Allegiance Health

🇺🇸

Jackson, Michigan, United States

Genesys Regional Medical Center-West Flint Campus

🇺🇸

Flint, Michigan, United States

Hurley Medical Center

🇺🇸

Flint, Michigan, United States

Sparrow Hospital

🇺🇸

Lansing, Michigan, United States

Saint Mary Mercy Hospital

🇺🇸

Livonia, Michigan, United States

William Beaumont Hospital-Royal Oak

🇺🇸

Royal Oak, Michigan, United States

Saint Joseph Mercy Oakland

🇺🇸

Pontiac, Michigan, United States

Saint Joseph Mercy Port Huron

🇺🇸

Port Huron, Michigan, United States

Saint Mary's of Michigan

🇺🇸

Saginaw, Michigan, United States

Saint John Macomb-Oakland Hospital

🇺🇸

Warren, Michigan, United States

Saint Luke's East - Lee's Summit

🇺🇸

Lee's Summit, Missouri, United States

Liberty Hospital

🇺🇸

Liberty, Missouri, United States

Heartland Regional Medical Center

🇺🇸

Saint Joseph, Missouri, United States

Montana Cancer Consortium CCOP

🇺🇸

Billings, Montana, United States

Northern Rockies Radiation Oncology Center

🇺🇸

Billings, Montana, United States

Billings Clinic Cancer Center

🇺🇸

Billings, Montana, United States

Saint Vincent Healthcare

🇺🇸

Billings, Montana, United States

Frontier Cancer Center and Blood Institute-Billings

🇺🇸

Billings, Montana, United States

Bozeman Deaconess Cancer Center

🇺🇸

Bozeman, Montana, United States

Benefis Healthcare- Sletten Cancer Institute

🇺🇸

Great Falls, Montana, United States

Great Falls Clinic

🇺🇸

Great Falls, Montana, United States

Bozeman Deaconess Hospital

🇺🇸

Bozeman, Montana, United States

Glacier Oncology PLLC

🇺🇸

Kalispell, Montana, United States

Berdeaux, Donald MD (UIA Investigator)

🇺🇸

Great Falls, Montana, United States

Saint Peter's Community Hospital

🇺🇸

Helena, Montana, United States

Kalispell Regional Medical Center

🇺🇸

Kalispell, Montana, United States

Montana Cancer Specialists

🇺🇸

Missoula, Montana, United States

Community Medical Hospital

🇺🇸

Missoula, Montana, United States

Saint Patrick Hospital - Community Hospital

🇺🇸

Missoula, Montana, United States

Mary Rutan Hospital

🇺🇸

Bellefontaine, Ohio, United States

Grant Medical Center

🇺🇸

Columbus, Ohio, United States

Adena Regional Medical Center

🇺🇸

Chillicothe, Ohio, United States

Mount Carmel Health Center West

🇺🇸

Columbus, Ohio, United States

Grady Memorial Hospital

🇺🇸

Delaware, Ohio, United States

Good Samaritan Hospital - Dayton

🇺🇸

Dayton, Ohio, United States

Miami Valley Hospital

🇺🇸

Dayton, Ohio, United States

Samaritan North Health Center

🇺🇸

Dayton, Ohio, United States

Blanchard Valley Hospital

🇺🇸

Findlay, Ohio, United States

Atrium Medical Center-Middletown Regional Hospital

🇺🇸

Franklin, Ohio, United States

Wayne Hospital

🇺🇸

Greenville, Ohio, United States

Marietta Memorial Hospital

🇺🇸

Marietta, Ohio, United States

Upper Valley Medical Center

🇺🇸

Troy, Ohio, United States

Springfield Regional Medical Center

🇺🇸

Springfield, Ohio, United States

Saint Ann's Hospital

🇺🇸

Westerville, Ohio, United States

Clinton Memorial Hospital

🇺🇸

Wilmington, Ohio, United States

Greene Memorial Hospital

🇺🇸

Xenia, Ohio, United States

Genesis HealthCare System

🇺🇸

Zanesville, Ohio, United States

AnMed Health Hospital

🇺🇸

Anderson, South Carolina, United States

Spartanburg Medical Center

🇺🇸

Spartanburg, South Carolina, United States

Wellmont Holston Valley Hospital and Medical Center

🇺🇸

Kingsport, Tennessee, United States

PeaceHealth Saint Joseph Medical Center

🇺🇸

Bellingham, Washington, United States

Harrison HealthPartners Hematology and Oncology-Bremerton

🇺🇸

Bremerton, Washington, United States

Kadlec Clinic Hematology and Oncology

🇺🇸

Kennewick, Washington, United States

Skagit Valley Hospital

🇺🇸

Mount Vernon, Washington, United States

Harrison HealthPartners Hematology and Oncology-Poulsbo

🇺🇸

Poulsbo, Washington, United States

Harborview Medical Center

🇺🇸

Seattle, Washington, United States

Minor and James Medical PLLC

🇺🇸

Seattle, Washington, United States

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

🇺🇸

Seattle, Washington, United States

Group Health Cooperative-Seattle

🇺🇸

Seattle, Washington, United States

Swedish Medical Center-First Hill

🇺🇸

Seattle, Washington, United States

The Polyclinic

🇺🇸

Seattle, Washington, United States

University of California Davis Comprehensive Cancer Center

🇺🇸

Sacramento, California, United States

Saint John Hospital and Medical Center

🇺🇸

Detroit, Michigan, United States

Saint Joseph Mercy Hospital

🇺🇸

Ann Arbor, Michigan, United States

Michigan Cancer Research Consortium CCOP

🇺🇸

Ann Arbor, Michigan, United States

Southeast Cancer Control Consortium

🇺🇸

Winston-Salem, North Carolina, United States

Dayton CCOP

🇺🇸

Dayton, Ohio, United States

Oncare Hawaii Inc-Kuakini

🇺🇸

Honolulu, Hawaii, United States

Kapiolani Medical Center for Women and Children

🇺🇸

Honolulu, Hawaii, United States

Saint Luke's Hospital of Kansas City

🇺🇸

Kansas City, Missouri, United States

Heartland Hematology and Oncology Associates Incorporated

🇺🇸

Kansas City, Missouri, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Cancer Center of Kansas-Wichita Medical Arts Tower

🇺🇸

Wichita, Kansas, United States

Grandview Hospital

🇺🇸

Dayton, Ohio, United States

Cancer Care Northwest - Spokane South

🇺🇸

Spokane, Washington, United States

Margaret R Pardee Memorial Hospital

🇺🇸

Hendersonville, North Carolina, United States

Fairfield Medical Center

🇺🇸

Lancaster, Ohio, United States

Cancer Center of Kansas - Salina

🇺🇸

Salina, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath